Healthcare Buzz: Arena Pharmaceuticals, VIVUS, Orexigen Therapeutics, Cell Therapeutics Inc

Lakeway, TX -- (SBWIRE) -- 02/20/2013 -- Bestdamnpennystocks, an investment community with a special focus on updating investors with recent news on the U.S. stock market, issues news alert on the following stocks:-

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) went down 0.24% and closed at $8.35. The 52-week range for the stock is $1.70 and $13.50. The Company has Price/Sales ratio of 65.44 and Price/Book ratio of 15.46. The 50-Day Moving Average and 200-Day Moving Average prices is $9.02 and $8.73 respectively.

How Should Investors Trade ARNA After The Recent Movement? Find Out Here

VIVUS, Inc. (NASDAQ:VVUS) soared 0.52% and closed at $13.46. So far this year, the stock is up over 0.3%. The 52-week range for the stock is $1.0 and $12.95. VIVUS, Inc. is a biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutic drugs for underserved markets, including obesity and related morbidities, such as sleep apnea and diabetes, and men's sexual health.

Is VVUS Strong Buy After The Recent Strong Gains? Get Free Trend Analysis Here

Orexigen Therapeutics, Inc. (NASDAQ:OREX) decreased 0.70% and closed at $5.65. The median Wall Street price target on the stock is $11.0 and the high target is set at $12.00 with majority of analysts have a buy rating on the company’s stock. The stock has the 50- Day Moving Average and 200-Day Moving Average prices of $5.90 and $5.29 respectively.

Is OREX a Buying Opportunity After The Recent Plunge? Don’t Miss Out Our Latest Report Here

Cell Therapeutics Inc. (NASDAQ:CTIC) slipped 2.08% and closed at $1.41. In the last one year, the stock is down over 79%. The 52-week range for the stock is $1.14 and $8.25. Cell Therapeutics develops acquires and commercializes treatments for cancer. The Company’s research, development, acquisition and in-licensing activities concentrate on identifying and developing new ways to treat cancer.

How Should Investors Trade CTIC After The Latest Earnings Report? Find Out Here

About bestdamnpennystocks.com
Best Damn Penny Stocks’ team is engaged in providing stock newsletters on various hot penny stocks on a regular basis. Our instant stock news on Major Gainers, small cap penny stocks and various other stocks, guides investors in making the wise stock market investments decision. In order to get update to the markets, we would advise you sign up to our free newsletters. You can become leader in stock market by keeping track of the daily activity.

Disclaimer
The assembled information disseminated by Bestdamnpennystocks.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Bestdamnpennystocks.com does expect that investors will buy and sell securities based on information assembled and presented in Bestdamnpennystocks.com. PLEASE always do your own due diligence, and consult your financial advisor.